Efficiency in management of organ dysfunction associated with infection by the novel SARS-CoV-2 virus through a personalized immunotherapy approach.
SAVE
Clinical Trial
suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL
ACHIEVE
Clinical Trial
ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 INFECTION EARLY: The ACHIEVE open-label non-randomized Cninical Trial
ACTIVATE II
Clinical Trial
A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ΒΥ COVID-19: THE ACTIVATE II TRIAL
SAVE-MORE
Clinical Trial
suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE-MORE DOUBLE-BLIND, RANDOMIZED, PHASE III CONFIRMATORY TRIAL